** Shares of drug developer Rapt Therapeutics RAPT.O fall 42.4% to $1.66
** Co says based on recent feedback from the U.S. FDA it has stopped development of its drug Zelnecirnon, for eczema and asthma
** The decision follows a clinical hold placed on the drug's trial by the FDA in February after a serious case of liver injury in one of the patients
** Co says it will identify a new experimental therapy to develop in H1 2025
** Including session's move, stock down 93.4%
(Reporting by Puyaan Singh and Christy Santhosh)
((Puyaan.Singh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.